United Therapeutics Balance Sheet
NASDAQ: UTHRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
United Therapeutics financial position
At the end of fiscal 2025, United Therapeutics reported total assets of $7.88 billion, up 7.0% from a year earlier against total liabilities of $783.8 million. Shareholders' equity stood at $7.10 billion, or 90.1% of assets. The company held $1.56 billion in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 6.60, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
United Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 1.56B | 1.70B | 1.21B | 961.20M | 894.80M | 738.70M | 738.40M | 669.20M | 705.10M | 1.02B |
| Short-Term Investments | 1.36B | 1.57B | 1.79B | 1.88B | 1.04B | 1.10B | 747.50M | 746.70M | 222.30M | 27.80M |
| Receivables | 350.20M | 279.30M | 278.90M | 220.40M | 198.70M | 157.40M | 151.40M | 175.70M | 297.10M | 214.50M |
| Inventory | 183.10M | 157.90M | 111.80M | 102.00M | 93.80M | 86.50M | 93.40M | 101.00M | 107.90M | 100.00M |
| Total Current Assets | 3.70B | 3.87B | 3.55B | 3.38B | 2.32B | 2.17B | 1.86B | 1.77B | 1.45B | 1.42B |
| Property, Plant & Equipment | 1.73B | 1.22B | 1.05B | 861.50M | 780.90M | 731.60M | 738.50M | 699.70M | 545.70M | 489.30M |
| Goodwill | 32.30M | 32.30M | 33.70M | 28.00M | 28.00M | 28.00M | 28.00M | 31.50M | 13.70M | 10.30M |
| Long-Term Investments | 1.78B | 1.48B | 1.91B | 1.32B | 1.65B | 1.15B | 767.50M | 442.60M | 502.70M | 2.30M |
| Total Assets | 7.88B | 7.36B | 7.17B | 6.04B | 5.17B | 4.62B | 3.91B | 3.40B | 2.88B | 2.33B |
| Accounts Payable | 7.10M | 6.00M | 5.60M | 4.10M | 3.80M | 4.10M | 9.90M | 23.10M | 8.40M | 8.10M |
| Total Current Liabilities | 560.60M | 738.10M | 804.40M | 343.20M | 305.40M | 323.30M | 463.00M | 276.60M | 444.70M | 332.50M |
| Total Liabilities | 783.80M | 920.00M | 1.18B | 1.25B | 1.21B | 1.22B | 1.13B | 593.20M | 758.40M | 463.40M |
| Shareholders' Equity | 7.10B | 6.44B | 5.98B | 4.80B | 3.96B | 3.40B | 2.78B | 2.79B | 2.10B | 1.85B |
| Retained Earnings | 8.56B | 7.22B | 6.03B | 5.04B | 4.32B | 3.84B | 3.33B | 3.43B | 2.85B | 2.43B |
| Net Cash (Debt) | 2.92B | 3.27B | 2.99B | 2.84B | 1.93B | 1.83B | 1.49B | 1.42B | 927.40M | 1.05B |
| Shares Outstanding | 43.64M | 44.83M | 47.04M | 46.03M | 45.11M | 44.51M | 43.88M | 43.59M | 43.24M | 42.97M |
This table shows 10 annual periods of United Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow UTHR's reporting calendar. What is a balance sheet?